New York-based AI biotechnology company Paige has entered into a collaboration with Janssen Research & Development to assess the potential of Janssen’s AI-powered biomarker test based on hematoxylin and eosin (H&E)—a widely used stain in medical diagnosis—in a clinical setting. The terms and financial details of the partnership have not been disclosed.
The partnership will leverage Paige’s platform in Janssen’s clinical trials to screen fibroblast growth factor receptor (FGFR) alterations in patients with bladder cancer. This is expected to accelerate patient recruitment by providing results within an hour, which otherwise takes weeks.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.